CRISPR is a new technology that has been discovered in the biotech industry. It offers a high likelihood of becoming a game-changer in biotech. CRISPR is a precise genome editing tool that has launched a host of new startups that are utilizing the technology to unlock medical innovations for advanced genetics-based diagnoses, treatments, and possibly even cures. Funding is on the rise for biotech companies using the technology as investors see the possibilities for these companies to grow exponentially in the months and years to come. There are exciting breakthroughs in medical science happening every day. This is also good news for investors who place their bets on the right startups. Here are 5 companies leading the way in CRISPR technology for your consideration.
1. CRISPR Therapeutics
CRISPR Therapeutics is listed under the ticker symbol CRSP. The company is high on the list of the most likely to succeed and thrive as it is found by co-discoverer of CRISPR technology, Emmanuelle Charpentier. Charpentier is also a co-recipient of the Nobel Prize in Chemistry for 2020. The company is leading the way in the new technology with a variety of therapies under development in the pipeline. The current focus is on the CTX001 treatment for patients diagnosed with sickle cell anemia disease. The second candidate is CTX110 for patients with relapsed/refractory non-Hodgkin lymphoma. It reached the end of Phase 1 trials with positive early results. Other candidates are under development and this company shows great promise for profitability in the months and years to come. CRISPR Therapeutics is a startup that merits watching by potential investors.
2. Editas Medicine
Editas Medicine is under the ticker symbol EDIT. This is an exciting new startup that focuses its attention on both types of gene editing methods. In vivo is a gene-editing technology that is accomplished while the genes are still in the body of the patient. Ex vivo takes place outside of the body and is then implanted into the patient. This company maintains strong developments and discoveries for both methods. This allows them to develop a broad range of treatments. Editas is currently focused on developing treatments for ocular diseases, cancers and blood diseases through CRISPER technology. They currently have multiple treatments in the pipeline that are in various stages of development and clinical trials. While the results are still pending, there is a high potential for Editas to emerge as a leader in the biotechnology industry. The company has a strong cash position with ample funding to run the business through the year 2023. Because of its strong financial backing and posturing, this is a company that serious investors are keeping an eye on, and it’s one that you may want to consider because of the high likelihood of profitability shortly. It only takes one breakthrough to catapult such a biotech company to the top of the list.
3. Intellia Therapeutics
Intellia Therapeutics is listed under the ticker symbol NTLA. The founder of the company is Jennifer Doudna, who worked alongside Emmanuelle Charpentier to develop the new CRISPR technology. She is a co-recipient of the 2020 Nobel Prize in Chemistry for the discovery of the technology. The discovery was made in 2012, and Intellia uses that technology to develop therapies to address a variety of genetic diseases. Intellia’s top candidate is an in vivo treatment for transthyretin amyloidosis, also known as ATTR. The name of the treatment is NTLS-2001, which is already in Phase 1 of clinical studies. A second candidate is NTLA-2002, developed for treating hereditary angioedema along with a treatment for acute myeloid leukemia called NTLA-5001. All three candidate therapies are in line for regulatory submission at some point in 2021. The progress that Intellia Therapeutics has made in the development of these three candidate therapies puts it in a strong position to become a leader in the CRISPR niche of the biotech industry.
4. Beam Therapeutics
Beam Therapeutics is listed as BEAM on the stock exchange. This company is a new startup in the CRISPR arena making its debut in February. Although it followed the market with a sink in shares earlier, it was merely following a trend with no reflection on the true potential of the company. Beam maintains a focus on base editing. This is a technique that changes the chemical compounds that make up DNA strands. This type of gene editing has the potential for erasing and rewriting genetic codes. Just by changing one letter of genetic code, the potential for creating new drugs that will yield positive results for the treatment of insidious diseases and genetic conditions is exciting and immense. Beam Therapeutics has sent its first new investigational drug to the USFDA for approval already. Shares have climbed by 190% since the business first launched and there is a good reason for excitement about its potential to thrive in a growing and expanding new niche of the biotech industry.
5. Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is listed under the ticker symbols REGN. This company is a bit different than most others in the CRISPR arena. Regeneron has spread its focus over several different areas of interest including asthma and dermatitis. It’s responsible for the development and marketing of the drug Dupixent, used to treat asthma. This alone propelled the company to a high spot in the leadership of the niche. The drug Eylea has been successful in treating multiple eye diseases and sales remain steady. A new candidate called Libtayo is under a priority review of the FDA for the treatment of cutaneous squamous cell carcinoma. Regeneron also has a treatment for the REGN-COV2 virus with trials for the therapy in their third quarter. Regeneron has already achieved a measure of success but with the adoption of new CRISPR technologies, the potential for Regeneron to experience significant growth. The new technology is an addition to the other established technologies that the company has successfully employed to date. Experts and analysts view the potential for Regeneron Pharmaceuticals as staggering. If you’re looking for a new inclusion to your current investment portfolio, this is one to definitely keep on the radar.